Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ipsen gets rights to Santhera's fipamezole; terminated

Executive Summary

Ipsen has received global development and marketing rights to Santhera Pharmaceuticals AG's (therapies for neuromuscular diseases) fipamezole for levodopa-induced dyskinesia in Parkinson's disease patients. The license excludes North America (where Biovail Corp. is the licensee) and Japan (where Santhera retains rights).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies